MAAT INDEX

CLAIM #48338 · Pfizer Inc (PFE) · 2023Q4 earnings call · Jan 30, 2024 · due Jan 30, 2026

That will ultimately improve gross margin rate as we cycle into later years.

David Denton · CFO

PENDING
graded after results covering Jan 30, 2026 are reported

In context

ve our margin rate and more importantly, improve our operating margin rate to the bottom-line. As we look here at 2024, there's a few things that have compressed our margin rate. First is, as COVID has declined year-over-year, that has served to, I'll say, delever, if you will, the P&L as COVID takes up and cover some fixed overhead. But importantly, what's happening is we are in sourcing products that we've recently acquired. That in sourcing requires time before we get up to peak yield and performance so that in the short-term, dampens gross margin rate, but has a trajectory to improve gross margin rate over time. And then secondly, we have new launches that are coming online late in Q3 -- late in the second half of 2023 and moving into '24. Again, those are not at peak performance yet. That will ultimately improve gross margin rate as we cycle into later years. And then finally, I will say that over the last several years, we have absorbed some amount of inflation within our cost of goods sold. That is an area of opportunity for us as we think about improving performance longer term. So I hope that gives you some color. Operator: Next, we have Carter Gould with Barclays. Carter Gould : Maybe another kind of finance question here. Certainly, R&D in 4Q was meaningfully below kind of where you guys had set the guide there. How should we think about that? Does it just reflect sort of faster cost cutting? Is it just more an artifact of the later integration of SGen? And clearly, you're reaffirming your guide but just maybe if you can just sort of check that box for us, that would be helpful. David Denton: Sure. Probably not much to read into that. Ob

Verify independently

SEC filings for PFE · Claim quote is verbatim from the 2023Q4 earnings call.